Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | CHKA | P35790 | 5/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | NCF1 | P14598 | 1/20 | 0.54 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148919 | 0.82 | KCNJ1 (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL14662334 | 0.82 | LMNA (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL4119541 | 0.82 | LMNA (0.61) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL3839191 | 0.80 | HRH3 (0.60) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL3451622 | 0.79 | LMNA (0.67) | LMNAMC4RCHKAHRH3CA2 | |
| SCHEMBL2359972 | 0.79 | HRH3 (0.67) | HRH3RAB9AALDH1A1 | |
| SCHEMBL2360324 | 0.79 | HRH3 (0.65) | LMNAHRH3ALDH1A1HPGD | |
| SCHEMBL29130396 | 0.79 | SIGMAR1 (0.59) | HRH3 | |
| SCHEMBL7299416 | 0.79 | KDM4E (0.61) | HRH3KDM4EALDH1A1 | |
| SCHEMBL18179384 | 0.78 | LMNA (0.56) | LMNAMC4RCHKAHRH3CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608791-B1 | A PROCESS FOR THE PREPARATION OF IMATINIB BASE | MUSTAFA NEVZAT ILAC SANAYII A S (TR) | 2016-05-18 | — | — | EP | claimed |
| EP-1599462-B1 | Process of preparing imatinib | CIPLA LTD (IN) | 2013-03-27 | — | — | EP | claimed |
| EP-2076507-A2 | IMATINIB BASE, AND IMATINIB MESYLATE AND PROCESSES FOR PREPARATION THEREOF | Sicor, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| JP-2009514988-A | — | — | 2009-04-09 | — | — | JP | claimed |
| EP-1966186-A1 | PROCESS FOR THE PREPARATION OF IMATINIB | Sicor Inc. (US) | 2008-09-10 | — | — | EP | claimed |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | SICOR INC. | 2008-08-28 | — | — | US | claimed |
| WO-2008057291-A2 | CRYSTALLINE AND AMORPHOUS IMATINIB BASE, IMATINIB MESYLATE- AND PROCESSES FOR PREPARATION THEREOF | SICOR INC. (US) | 2008-05-15 | — | — | WO | claimed |
| WO-2008051597-A1 | PROCESS FOR THE PREPARATION OF IMATINIB | SICOR INC. (US) | 2008-05-02 | — | — | WO | claimed |
| US-20080103305-A1 | Process for the preparation of imatinib | SICOR INC. | 2008-05-01 | — | — | US | claimed |
| CN-105560246-B | The preparation and its pharmaceutical composition of imatinib mesylate α crystallization | 正大天晴药业集团南京顺欣制药有限公司 | 2019-07-26 | — | — | CN | disclosed |
| CN-102731474-B | Preparation method of imatinib | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN | 2014-12-03 | — | — | CN | disclosed |
| WO-2013035102-A1 | PROCESSES FOR THE PREPARATION OF IMATINIB BASE AND INTERMEDIATES THEREOF | NATCO PHARMA LIMITED (IN) | 2013-03-14 | — | — | WO | disclosed |
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| WO-2004074502-A3 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004074502-A2 | A PROCESS OF PREPARING IMATINIB | CIPLA LTD (IN) | 2004-09-02 | — | — | WO | disclosed |
| EP-0767798-B1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK AS (DK) | 2003-09-03 | — | — | EP | disclosed |
| US-20030004148-A1 | Regulation of meiosis | NOVO NORDISK A/S (DK) | 2003-01-02 | — | — | US | disclosed |
| EP-0767798-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000235-A1 | STEROL DERIVATIVES USED FOR REGULATION OF MEIOSIS | NOVO NORDISK A/S (DK) | 1996-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103305-A1 | Process for the preparation of imatinib | ABL1, ABL2, PDGFRA | LMNA 3432/4885MC4R 4351/4885CHKA 3324/4885 |
| US-20030004148-A1 | Regulation of meiosis | ALPG, MNS1, BUB1B | LMNA 946/4885MC4R 4207/4885CHKA 1903/4885 |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | LMNA 1676/4885MC4R 4718/4885CHKA 3017/4885 |
| US-20080207904-A1 | Imatinib base, and imatinib mesylate and processes for preparation thereof | ABL1, ABL2, MET | LMNA 2886/4885MC4R 3859/4885CHKA 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.